Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Pharmacokinetic Effect of Y-3 for Injection on Repaglinide Tablets, Warfarin Sodium Tablets, and Omeprazole Enteric-Coated Capsules in Healthy Participants

NCT07068841 is registered in ClinicalTrials.gov with Neurodawn Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07068841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07068841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Pharmacokinetic Effect of Y-3 for Injection on Repaglinide Tablets, Warfarin Sodium Tablets, and Omeprazole Enteric-Coated Capsules in Healthy Participants
Lead sponsor
Neurodawn Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
May 18, 2025
Completion date
June 29, 2025
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug-drug interaction, omeprazole enteric-coated capsules, pharmacokinetic profiles, repaglinide tablets, safty, warfarin sodium tablets, y-3 for injection